Light-chain cardiac amyloidosis for the non-expert: pearls and pitfalls.


Journal

Internal and emergency medicine
ISSN: 1970-9366
Titre abrégé: Intern Emerg Med
Pays: Italy
ID NLM: 101263418

Informations de publication

Date de publication:
10 2023
Historique:
received: 11 01 2023
accepted: 01 06 2023
medline: 2 10 2023
pubmed: 20 6 2023
entrez: 20 6 2023
Statut: ppublish

Résumé

Cardiac amyloidosis (CA) is an uncommon, progressive, and fatal disease; the two main forms that can affect the heart are transthyretin CA and light chain CA (AL-CA). AL-CA is a medical urgency for which a diagnostic delay can be catastrophic for patients' outcome. In this manuscript, we focus on the pearls and pitfalls that are relevant to achieve a correct diagnosis and to avoid diagnostic and therapeutical delays. Through the aid of three unfortunate clinical cases, some fundamental diagnostic aspects are addressed, including the following: first, a negative bone scintigraphy does not exclude CA, with patients with AL-CA frequently showing no or mild cardiac uptake, and its execution should not delay hematological tests; second, fat pad biopsy does not have a 100% sensitivity for AL amyloidosis and, if negative, further investigations should be performed, particularly if the pre-test probability is high. Third, Congo Red staining is not sufficient to reach a definitive diagnosis and amyloid fibrils typing with mass spectrometry, immunohistochemistry, or immunoelectron microscopy is crucial. To achieve a timely and correct diagnosis, all the necessary investigations must be performed, always considering the yield and diagnostic accuracy of each examination.

Identifiants

pubmed: 37338717
doi: 10.1007/s11739-023-03335-3
pii: 10.1007/s11739-023-03335-3
pmc: PMC10543940
doi:

Substances chimiques

Congo Red 3U05FHG59S

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

1879-1886

Informations de copyright

© 2023. The Author(s).

Références

Circulation. 2016 Jun 14;133(24):2404-12
pubmed: 27143678
Circulation. 2022 May 3;145(18):e895-e1032
pubmed: 35363499
Nat Rev Dis Primers. 2018 Oct 25;4(1):38
pubmed: 30361521
Eur J Heart Fail. 2023 Mar;25(3):335-346
pubmed: 36597836
JACC CardioOncol. 2022 Nov 15;4(4):427-441
pubmed: 36444232
Heart. 2012 Oct;98(19):1442-8
pubmed: 22865865
JACC CardioOncol. 2019 Sep 24;1(1):117-130
pubmed: 34396169
Amyloid. 2023 Mar;30(1):3-17
pubmed: 35838162
Blood. 2019 Feb 14;133(7):763-766
pubmed: 30545829
JACC CardioOncol. 2020 Mar 17;2(1):127-130
pubmed: 34396218
Blood Cancer J. 2019 Mar 5;9(3):30
pubmed: 30837451
Eur Heart J. 2023 Jun 25;44(24):2187-2198
pubmed: 36946431
N Engl J Med. 2018 Sep 13;379(11):1007-1016
pubmed: 30145929
J Clin Oncol. 2012 Mar 20;30(9):989-95
pubmed: 22331953
J Am Coll Cardiol. 2005 Sep 20;46(6):1076-84
pubmed: 16168294
JACC Cardiovasc Imaging. 2020 Jun;13(6):1314-1321
pubmed: 31864976
Heart. 2017 Jul;103(14):1065-1072
pubmed: 28456755
Eur Heart J Cardiovasc Imaging. 2016 Sep;17(9):970-7
pubmed: 27225804
J Clin Oncol. 2004 Sep 15;22(18):3751-7
pubmed: 15365071
J Intern Med. 2015 May;277(5):605-14
pubmed: 25346163
Blood. 2020 Dec 3;136(23):2620-2627
pubmed: 33270858
Blood Cancer J. 2021 Jun 21;11(6):118
pubmed: 34155191
JACC Cardiovasc Imaging. 2023 Apr;16(4):464-477
pubmed: 36648052
Cardiovasc Res. 2023 Feb 3;118(18):3517-3535
pubmed: 35929637
Intern Emerg Med. 2022 Jun;17(4):957-969
pubmed: 35325395
Circ Heart Fail. 2021 Apr;14(4):e008225
pubmed: 33736459
J Am Coll Cardiol. 2020 Jun 9;75(22):2851-2862
pubmed: 32498813
J Card Fail. 2019 Nov;25(11):e1-e39
pubmed: 31473268
Adv Ther. 2015 Oct;32(10):920-8
pubmed: 26498944
Eur Heart J. 2021 Sep 21;42(36):3599-3726
pubmed: 34447992
Ann Med. 2017 Nov;49(7):545-551
pubmed: 28271734
Trends Cardiovasc Med. 2023 Feb 24;:
pubmed: 36841466
Eur Heart J. 2021 Apr 21;42(16):1554-1568
pubmed: 33825853
Circulation. 2020 Jul 7;142(1):e7-e22
pubmed: 32476490
JACC CardioOncol. 2022 Sep 07;4(4):458-470
pubmed: 36444225
Circulation. 2009 Sep 29;120(13):1203-12
pubmed: 19752327
Intern Emerg Med. 2013 Apr;8(3):191-203
pubmed: 21739229

Auteurs

Laura De Michieli (L)

Department of Cardiac, Thoracic and Vascular Sciences and Public Health, University of Padova, Via Giustiniani, 2, 35128, Padua, Italy. laura.demichieli@phd.unipd.it.

Giulio Sinigiani (G)

Department of Cardiac, Thoracic and Vascular Sciences and Public Health, University of Padova, Via Giustiniani, 2, 35128, Padua, Italy.

Monica De Gaspari (M)

Department of Cardiac, Thoracic and Vascular Sciences and Public Health, University of Padova, Via Giustiniani, 2, 35128, Padua, Italy.
Cardiovascular Pathology Unit, University Hospital of Padua, Padua, Italy.

Antonio Branca (A)

Hematology and Clinical Immunology Branch, Department of Medicine, University of Padova, Padua, Italy.

Stefania Rizzo (S)

Department of Cardiac, Thoracic and Vascular Sciences and Public Health, University of Padova, Via Giustiniani, 2, 35128, Padua, Italy.
Cardiovascular Pathology Unit, University Hospital of Padua, Padua, Italy.

Cristina Basso (C)

Department of Cardiac, Thoracic and Vascular Sciences and Public Health, University of Padova, Via Giustiniani, 2, 35128, Padua, Italy.
Cardiovascular Pathology Unit, University Hospital of Padua, Padua, Italy.

Livio Trentin (L)

Hematology and Clinical Immunology Branch, Department of Medicine, University of Padova, Padua, Italy.

Sabino Iliceto (S)

Department of Cardiac, Thoracic and Vascular Sciences and Public Health, University of Padova, Via Giustiniani, 2, 35128, Padua, Italy.
Cardiology Unit, University Hospital of Padua, Padua, Italy.

Martina Perazzolo Marra (M)

Department of Cardiac, Thoracic and Vascular Sciences and Public Health, University of Padova, Via Giustiniani, 2, 35128, Padua, Italy.
Cardiology Unit, University Hospital of Padua, Padua, Italy.

Alberto Cipriani (A)

Department of Cardiac, Thoracic and Vascular Sciences and Public Health, University of Padova, Via Giustiniani, 2, 35128, Padua, Italy.
Cardiology Unit, University Hospital of Padua, Padua, Italy.

Tamara Berno (T)

Hematology and Clinical Immunology Branch, Department of Medicine, University of Padova, Padua, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH